[DERM] Dermira, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 30.57 Change: 0.63 (2.1%)
Ext. hours: Change: 0 (0%)

chart DERM

Refresh chart

Strongest Trends Summary For DERM

DERM is in the medium-term down -41% below S&P in 2 months and down -63% below S&P in 8 months. In the long-term down -89% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company?s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-17.27% ROE-20.31% ROI
Current Ratio10.38 Quick Ratio Long Term Debt/Equity0.02 Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities40 K Cash From Investing Activities1.86 M Cash From Operating Activities-5.12 M Gross Profit
Net Profit-14.04 M Operating Profit-14.23 M Total Assets165.61 M Total Current Assets124.49 M
Total Current Liabilities12 M Total Debt1.94 M Total Liabilities24.75 M Total Revenue
Technical Data
High 52 week14.82 Low 52 week5.31 Last close5.31 Last change0%
RSI18.73 Average true range0.46 Beta1.1 Volume98.87 K
Simple moving average 20 days-18.35% Simple moving average 50 days-30.51% Simple moving average 200 days-40.72%
Performance Data
Performance Week-7.17% Performance Month-40.67% Performance Quart-38.04% Performance Half-55.27%
Performance Year-54.54% Performance Year-to-date-26.15% Volatility daily3.7% Volatility weekly8.28%
Volatility monthly16.97% Volatility yearly58.78% Relative Volume231.19% Average Volume645.15 K
New High New Low

News

2019-11-14 16:05:00 | Dermira Presents New Scientific Research Findings from the Lebrikizumab Program at Leading International Itch Conference

2019-11-13 16:05:00 | Dermira Elects Halley E. Gilbert to its Board of Directors

2019-11-11 16:10:00 | Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day

2019-11-08 16:05:00 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-11-08 10:18:03 | Short Seller Scores Big Win as Tiny Biotech Stock Sinks 72%

2019-11-08 10:04:03 | The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

2019-11-08 08:00:01 | Pharma Sector Tops in October: Best ETFs & Stocks

2019-11-07 09:17:02 | Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks

2019-11-07 06:07:36 | 3 Biotech Stocks Needham Expects to Double in the Next 12 Months

2019-11-06 10:36:03 | Jazz Pharma JAZZ Q3 Earnings Beat, Xyrem Drives Sales

2019-11-06 02:08:21 | Edited Transcript of DERM earnings conference call or presentation 5-Nov-19 9:30pm GMT

2019-11-05 19:15:12 | Dermira DERM Reports Q3 Loss, Tops Revenue Estimates

2019-11-05 16:05:00 | Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update

2019-10-29 16:05:00 | Dermira to Report Third Quarter 2019 Results and Host Conference Call on Tuesday, November 5, 2019

2019-10-25 09:03:58 | Did You Manage To Avoid Dermira's NASDAQ:DERM Devastating 79% Share Price Drop?

2019-10-18 10:23:24 | These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year

2019-10-17 16:05:00 | Dermira Presents Data From Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference

2019-10-14 10:28:02 | Aclaris Divests Rhofade to EPI Health for $55M, Shares Up

2019-10-10 09:57:01 | Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study

2019-10-10 08:30:00 | Dermira to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference

2019-10-09 08:30:00 | Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

2019-10-08 16:05:00 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-09-26 16:05:00 | Dermira to Participate in the 2019 Cantor Global Healthcare Conference

2019-09-10 12:24:45 | How Much Are Dermira, Inc. NASDAQ:DERM Insiders Spending On Buying Shares?

2019-08-29 16:05:00 | Dermira to Participate in Upcoming Investor Conferences

2019-08-20 00:15:17 | Dermira Inc DERM CEO & Chairman of the Board Thomas G Wiggans Bought $199,998 of Shares

2019-08-08 12:00:08 | Edited Transcript of DERM earnings conference call or presentation 7-Aug-19 8:30pm GMT

2019-08-07 19:45:11 | Dermira DERM Reports Q2 Loss, Tops Revenue Estimates

2019-08-07 16:05:00 | Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update

2019-07-31 16:05:00 | Dermira to Report Second Quarter 2019 Results and Host Conference Call on Wednesday, August 7, 2019

2019-07-29 10:34:02 | Earnings Preview: Dermira DERM Q2 Earnings Expected to Decline

2019-07-25 13:03:48 | 5 Biotech Stocks to Buy for Blockbuster Potential

2019-07-24 15:15:48 | Should You Be Pleased About The CEO Pay At Dermira, Inc.'s NASDAQ:DERM

2019-07-01 09:15:01 | Stocks Soar 7% in June

2019-06-25 01:30:00 | Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis

2019-06-11 16:00:00 | Dermira to Present at the Raymond James Life Sciences and MedTech Conference

2019-06-11 08:05:48 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-06-10 08:05:02 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-06-06 13:34:00 | Dermira Advances on Analyst Upgrade to Buy

2019-06-06 08:05:15 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-06-04 08:03:27 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-05-08 15:24:17 | Dermira DERM Q1 2019 Earnings Call Transcript

2019-05-08 11:13:10 | Did You Manage To Avoid Dermira's NASDAQ:DERM Painful 63% Share Price Drop?

2019-05-08 01:11:11 | Edited Transcript of DERM earnings conference call or presentation 7-May-19 8:30pm GMT

2019-05-07 19:25:11 | Dermira DERM Reports Q1 Loss, Lags Revenue Estimates

2019-05-07 18:19:15 | Dermira: 1Q Earnings Snapshot

2019-05-07 16:05:00 | Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update

2019-05-07 08:03:19 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-04-30 16:05:00 | Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019

2019-04-25 10:34:02 | Dermira DERM May Report Negative Earnings: Know the Trend Ahead of Q1 Release